Kurs
+2,94%
Kurs
+2,94%
Open
0,98
High
1,00
Low
0,94
Close
0,94
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,45 MNOK
Likviditet
0,45 MNOK
Rel. mcap
0,06%
Antal aktier
470 934
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-04-24 | N/A | Årsstämma |
| 2025-02-26 | 07:00 | Bokslutskommuniké 2024 |
| 2025-01-06 | N/A | Extra Bolagsstämma 2025 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2024-04-11 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2023-04-26 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-03-01 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | 15-10 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | - | Årsstämma |
| 2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2021-03-22 | - | Extra Bolagsstämma 2021 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-21 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-06-10 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-18 | - | Extra Bolagsstämma 2019 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-30 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-12-20 | - | Extra Bolagsstämma 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-10-12 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | Kapitalmarknadsdag 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kapitalmarknadsdag 2015 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-27 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-09 | - | Årsstämma |
| 2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2024-03-14 08:17:19
14.3.2024 08:17:16 CET | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state
Thor Medical ASA has been awarded to receive as grant NOK 6 million from
Innovation Norway related to the establishment of a class-B laboratory and pilot
plant for production of high-purity Thorium-228 alpha-emitters at Herøya
Industripark.
The facilities are already under construction for commissioning in the second
half of the year. The pilot plant will enable Thor Medical to verify products
and proprietary processes and to produce customer samples for qualification.
"We are very pleased to receive this grant as it will enable us to accelerate
our industrial development at Herøya, and take it as sign of recognition from
Innovation Norway to our ambition and business plan to become a leading supplier
of alpha emitters for cancer therapy", says Alf Bjørseth, CEO of Thor Medical
ASA.
Upon customer qualification Thor Medical expects to convert current LOIs for
future offtake agreements into firm supply contracts, which in turn will
contribute to enabling the company to make an investment decision for its first
industrial-scale manufacturing facility for Thorium-228 next year.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2972/4187/Download%20announcement
%20as%20PDF.pdf